Emergency physicians wrote 12% fewer prescriptions per month after guidelines were disseminated.
The opioid epidemic has prompted a surge of new guidelines and regulations. But do these interventions work? In 2012, Ohio promulgated a guideline on opioid prescribing that was developed by a collaboration of government, public health, hospital, and medical groups. To determine whether implementation of the guideline affected opioid prescribing by emergency physicians, investigators analyzed data from Ohio's prescription drug monitoring program between 2010 and 2014. The analysis focused on the five most commonly prescribed opioids.
After implementation of the guidelines, there was a 12% reduction in opioid prescriptions by emergency physicians per month, and an 11% monthly reduction in prescriptions for greater than a 3-day supply.
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals